For Year 2025-26, Aspira Pathlab & Diagnostics reports the following shareholding: Total Promoters at 18.39%, Mutual Fund at 0%, Insurance at 0%, Foreign Institutional Investors at 0%, Domestic Institutional Investors at 0%, and Retail at 81.61%. This breakdown provides a quick snapshot of ownership distribution for Aspira Pathlab & Diagnostics in 2025-26.